Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: acute lymphoblastic leukemia
Age: Between 0 - 99 Years
Gender: Male or Female
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com